News & events - Mendus

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

Press Releases
No articles found

Events
8 November 2024
Previous
Third quarter 2024 financial report and business updateLive audiocast 14:00 CET November 8, 2024  
More details
October 2024Previous
Mendus CEO Erik Manting presented at the LSX Nordic Congress 2024 held on October 9, 2024
More details
September 2024Previous
Mendus CEO Erik Manting presented at the H.C. Wainwright 26th Annual Global Investment Conference held on September 9, 2024
More details
August 2024Previous
Second quarter 2024 financial report and business update
Live audiocast 10:00 CEST August 23, 2024  
More details
April 2024Previous
Mendus CEO Erik Manting presented at the Invest in Oncology Forum held in Stockholm on April 10, 2024
More details
March 2024Previous
Mendus business update and outlook for vididencel program
Mendus held a business update and outlook for the development of its lead product vididencel in acute myeloid leukemia (AML) during a live investor event on March 12, 15.00-17.00 CET.

The replay of the event is accessible via the link below.
More details
March 2024Previous
CEO Erik Manting interview at Inderes on March 12, 2024
More details

Interviews
19 December 2024
Analyst interview – EdisonCEO Erik Manting talks about the recent progress in developing Mendus’ lead product vididencel as an active immunotherapy for acute myeloid leukemia and additional indications, in an interview with Edison analyst Arron Aatkar,
Watch
December 2024
Analyst interview – Redeye
CEO Erik Manting speaks with Redeye analyst Christian Binder about the positive survival update of the ADVANCE II Phase 2 trial with vididencel in AML and other abstracts presented at ASH24 
Watch
December 2024
Investor Update – Investor Studios
CEO Erik Manting talks about the latest data of the ADVANCE II Phase 2 trial presented at ASH 2024, demonstrating durable survival of AML patients treated with Mendus lead product vididencel.
Watch
December 2024
Redeye Technology & Life Science Day
CEO Erik Manting presents at Redeye Technology & Life Science Day 2024 – December 3
Watch
November 2024
Biotech TV – BioEurope
CEO Erik Manting talks about immunotherapy in AML in an interview with Biotech TV at BIO-Europe
Watch
August 2024
Analyst interview – Edison
August 23

CEO Erik Manting talks about the company’s exciting recent developments and future plans in an interview with Edison's Soo Romanoff
Watch
June 2024
Analyst interview – Redeye
CEO Erik Manting talks about the latest data presented at EHA demonstrating the link between functional immune responses and long-term survival in AML patients treated with Mendus lead product vididencel
Watch

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi-1818292058-cSupnp451bkryVj385ceB7:before { opacity: 1; background-image: url('/static/9374a44515aa9e27ec32f6b9282ea2f7/d3468/NewsEvents_2_mobile.jpg'); }

Investors